This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trichopoulos, D. Articles by Boffetta, P. Search for Related Content PubMed PubMed Citation Articles by Trichopoulos, D. Articles by Boffetta, P.

Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from Greece

¹ Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; ² Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece; and ³ IARC, Lyon, France

Requests for reprints: Paolo Boffetta, Unit of Environmental Cancer Epidemiology, IARC, 150 cours Albert Thomas, 69008 Lyon, France. Phone: 33-47273-8554; Fax: 33-47273-8320. E-mail: boffetta{at}iarc.fr

Background: Inflammation is an important component of carcinogenesis but little research has been conducted on whether inflammation markers can be predictive of cancer risk in humans.

Methods: We analyzed C-reactive protein (CRP), a marker of inflammation, in plasma samples of 496 cases of cancer and 996 controls selected among participants in a prospective study from Greece.

Results: Plasma CRP level was higher in cancer cases than controls (odds ratio for increase in CRP level of 3.2 mg/L, 1.20; 95% confidence interval, 1.10-1.32): The corresponding odds ratio after exclusion of the first year of follow-up and of individuals with CRP level above 20 mg/L was 1.32 (95% confidence interval, 1.15-1.52). Although based on small number of cases, the association between elevated plasma CRP level and risk was stronger for cancers of the liver, lung, skin, kidney, and bladder, as well as for lymphoma and leukemia than for other neoplasms.

Conclusions: Our results confirm the important role of inflammation in human cancer and suggest that plasma CRP level is a potential marker of increased cancer risk. (Cancer Epidemiol Biomarkers Prev 2006;15(2):381–4)

This article has been cited by other articles:

				W. Koenig, N. Khuseyinova, J. Baumert, and C. Meisinger Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998 Clin. Chem., February 1, 2008; 54(2): 335 - 342. [Abstract] [Full Text] [PDF]

				K. Heikkila, S. Ebrahim, and D. A Lawlor A systematic review of the association between circulating concentrations of C reactive protein and cancer J. Epidemiol. Community Health, September 1, 2007; 61(9): 824 - 833. [Abstract] [Full Text] [PDF]

				S. M. Zhang, J. Lin, N. R. Cook, I-M. Lee, J. E. Manson, J. E. Buring, and P. M. Ridker C-Reactive Protein and Risk of Breast Cancer J Natl Cancer Inst, June 6, 2007; 99(11): 890 - 894. [Abstract] [Full Text] [PDF]